MoS2@C nanosphere as near infrared / pH dual response platform for chemical photothermal combination treatment

Xiao Zhang, Zhihuan Zhao, Pengfei Yang, Wen Liu, Jimin Fan, Bing Zhang, Shu Yin

    Research output: Contribution to journalArticlepeer-review

    11 Citations (Scopus)

    Abstract

    The three-dimensional urchin-like MoS2@C nanocomposite was successfully synthesized via one-step hydrothermal synthesis approach. The as-prepared MoS2@C nanoparticles exhibits strong absorb, high photothermal conversion ability (40.8 %), superb biocompatibility and high drug loading capacity for doxorubicin (52.34 %). In vitro drug release experiments show a pH, temperature and near infrared laser-triggered doxorubicinhydro release profile that enhances therapeutic anticancer effects. The drug release curve increased step by step under laser irradiation, and the accumulative delivery amount reached to 64.59 %, which was about 2 times of that without laser irradiation. By using DOX-loaded nano-platform, effective synergistic photothermal therapy for cancer can be achieved and has been systematically verified in vitro. Cell viability experiments showed that the survival rate of cells with MoS2 @C-DOX was only 25.8 %. Therefore, this work presents carbon-based nanoparticles with significant characteristics and is used as a highly potential therapeutic nano-platform for cancer treatment.

    Original languageEnglish
    Article number111054
    JournalColloids and Surfaces B: Biointerfaces
    Volume192
    DOIs
    Publication statusPublished - 2020 Aug

    Keywords

    • Carbon sphere
    • Chemotherapy
    • MoS@C-DOX
    • Photothermal therapy

    ASJC Scopus subject areas

    • Biotechnology
    • Surfaces and Interfaces
    • Physical and Theoretical Chemistry
    • Colloid and Surface Chemistry

    Fingerprint

    Dive into the research topics of 'MoS2@C nanosphere as near infrared / pH dual response platform for chemical photothermal combination treatment'. Together they form a unique fingerprint.

    Cite this